American Journal of Health-System Pharmacy
March 4, 2026
Jennifer E. Thomas, Anna Dellarole, Robin J Jacobs
MDMA and ketamine IV currently have the greatest support in the literature for efficacy in PTSD. Studies suggest treatment with these agents under supervision may lead to improvements in PTSD symptoms, with the medications being generally well tolerated. However, caution should be used when interpreting study results due to limitations such as treatment expectancy effect and the potential for...
Cureus
September 1, 2023
Nm Mahmudul Alam Bhuiya, Robin J Jacobs, Karina Wang et al.
3 citations
Background Psilocybin has been studied for its potential therapeutic benefits, particularly for the treatment of psychiatric disorders such as anxiety, depression, and obsessive-compulsive disorder. While more research is needed as psilocybin-assisted therapy becomes more prevalent, future pharmacists will probably be involved at some level. At present, pharmacists receive minimal training on...
Cureus
April 1, 2023
Karina Wang, Yiqun Sun, Brenda Nava et al.
14 citations
Background Psilocybin use, along with other psychedelics, has seen an increased interest among professionals in the medical community due to its potential therapeutic benefits for psychiatric disorders, substance use disorders (SUD), and palliative care. While it is certain that more research is necessary as psychedelic-assisted therapy becomes more prevalent, it will most likely be future...
Cureus
March 30, 2022
Carolina Sepulveda Ramos, Matthew P. Thornburg, Kelly A Long et al.
9 citations
Ketamine, a non-competitive N-methyl-d-aspartate receptor antagonist, is commonly used as an anesthetic and analgesic but has recently shown promising research in treating certain psychiatric conditions such as depression, post-traumatic stress disorder (PTSD), suicidal ideation, and substance use disorder. Due to its euphoric, dissociative, and hallucinogenic properties, ketamine has been...